0.20Open0.20Pre Close369 Volume581 Open Interest2.50Strike Price11.85KTurnover101.98%IV9.76%PremiumAug 16, 2024Expiry Date0.04Intrinsic Value100Multiplier24DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type-0.4677Delta0.6172Gamma8.95Leverage Ratio-0.0052Theta-0.0008Rho-4.18Eff Leverage0.0025Vega
Cellectar BioSciences Stock Discussion
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 202...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
4 MINUTES AGO, 6:40 AM EST
VIA GLOBENEWSWIRE
No comment yet